Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies
BackgroundCardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarker...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477679/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103881812410368 |
|---|---|
| author | Cuncun Chen Hui Zheng Yanchun Wang Ying Tong Heng Zhang Suhong Xie Xiaolu Ma Minglei Jiang Zhiyun Gong Tianqing Yan Yanan Tian Lin Guo Renquan Lu |
| author_facet | Cuncun Chen Hui Zheng Yanchun Wang Ying Tong Heng Zhang Suhong Xie Xiaolu Ma Minglei Jiang Zhiyun Gong Tianqing Yan Yanan Tian Lin Guo Renquan Lu |
| author_sort | Cuncun Chen |
| collection | DOAJ |
| description | BackgroundCardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarkers during chemotherapy and their association with chemotherapy-related cardiac toxicity.MethodsIn a prospective cohort of 73 patients treated with anthracycline-containing chemotherapy, soluble suppression of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myoglobin, creatine kinase isoenzyme MB, and heart-fatty acid binding protein were measured at baseline, during chemotherapy cycle (C1–C6). According to whether arrhythmia occurred, patients were divided into two groups (healthy group or arrhythmias group), and basic clinical characteristics were collected and compared. Logistic regression analyses and receiver operating characteristic (ROC) curves were conducted to investigate the association between the changes in biomarkers and arrhythmia.ResultssST2 levels increased significantly from baseline to C1 (P < 0.01). NT-proBNP levels decreased from baseline to C1 and C5 (P < 0.01). The logistic regression analysis showed a greater risk of arrhythmia was associated with interval changes in sST2 [odds ratio (OR): 1.27; 95% CI: 1.03–1.56; P = 0.024] and NT-proBNP (OR: 0.83; 95% CI: 0.70–0.98; P = 0.029). The ROC curves showed that ΔsST2, ΔNT-proBNP, and ΔsST2 + ΔNT-proBNP had good predictive value for arrhythmia (areas under the curves were 0.631, 0.633, and 0.735, respectively, P < 0.05).ConclusionsEarly changes in sST2 and NT-proBNP levels offer additive information for early arrhythmia prediction in breast cancer patients who receive anthracycline-containing chemotherapy. |
| format | Article |
| id | doaj-art-2affb666a5304d2dafe137bc82950a9a |
| institution | DOAJ |
| issn | 2297-055X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-2affb666a5304d2dafe137bc82950a9a2025-08-20T02:39:27ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2024-12-011110.3389/fcvm.2024.14776791477679Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapiesCuncun ChenHui ZhengYanchun WangYing TongHeng ZhangSuhong XieXiaolu MaMinglei JiangZhiyun GongTianqing YanYanan TianLin GuoRenquan LuBackgroundCardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarkers during chemotherapy and their association with chemotherapy-related cardiac toxicity.MethodsIn a prospective cohort of 73 patients treated with anthracycline-containing chemotherapy, soluble suppression of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myoglobin, creatine kinase isoenzyme MB, and heart-fatty acid binding protein were measured at baseline, during chemotherapy cycle (C1–C6). According to whether arrhythmia occurred, patients were divided into two groups (healthy group or arrhythmias group), and basic clinical characteristics were collected and compared. Logistic regression analyses and receiver operating characteristic (ROC) curves were conducted to investigate the association between the changes in biomarkers and arrhythmia.ResultssST2 levels increased significantly from baseline to C1 (P < 0.01). NT-proBNP levels decreased from baseline to C1 and C5 (P < 0.01). The logistic regression analysis showed a greater risk of arrhythmia was associated with interval changes in sST2 [odds ratio (OR): 1.27; 95% CI: 1.03–1.56; P = 0.024] and NT-proBNP (OR: 0.83; 95% CI: 0.70–0.98; P = 0.029). The ROC curves showed that ΔsST2, ΔNT-proBNP, and ΔsST2 + ΔNT-proBNP had good predictive value for arrhythmia (areas under the curves were 0.631, 0.633, and 0.735, respectively, P < 0.05).ConclusionsEarly changes in sST2 and NT-proBNP levels offer additive information for early arrhythmia prediction in breast cancer patients who receive anthracycline-containing chemotherapy.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477679/fullsoluble ST2NT-ProBNPcardiac toxicityarrhythmiachemotherapy |
| spellingShingle | Cuncun Chen Hui Zheng Yanchun Wang Ying Tong Heng Zhang Suhong Xie Xiaolu Ma Minglei Jiang Zhiyun Gong Tianqing Yan Yanan Tian Lin Guo Renquan Lu Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies Frontiers in Cardiovascular Medicine soluble ST2 NT-ProBNP cardiac toxicity arrhythmia chemotherapy |
| title | Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies |
| title_full | Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies |
| title_fullStr | Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies |
| title_full_unstemmed | Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies |
| title_short | Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies |
| title_sort | changes in sst2 and nt probnp levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline containing chemotherapies |
| topic | soluble ST2 NT-ProBNP cardiac toxicity arrhythmia chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477679/full |
| work_keys_str_mv | AT cuncunchen changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT huizheng changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT yanchunwang changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT yingtong changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT hengzhang changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT suhongxie changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT xiaoluma changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT mingleijiang changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT zhiyungong changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT tianqingyan changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT yanantian changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT linguo changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies AT renquanlu changesinsst2andntprobnplevelspredictearlycardiacarrhythmiainbreastcancerpatientstreatedwithanthracyclinecontainingchemotherapies |